Ubs Group Ag Allovir, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALVR
# of Institutions
63Shares Held
44.6MCall Options Held
14.9KPut Options Held
200-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$5.08 Million0.4% of portfolio
-
Octagon Capital Advisors LP New York, NY11.2MShares$5.04 Million2.19% of portfolio
-
Siren, L.L.C. New York, NY6.6MShares$2.97 Million0.27% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.28MShares$1.48 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.65MShares$1.19 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $41.9M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...